Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

STAT3 inhibitor VVD-130850

An orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), with potential antineoplastic activity. Upon oral administration, STAT3 inhibitor VVD-130850 targets and binds to an allosteric pocket of STAT3. This prevents STAT3 binding to responsive gene promoters, STAT3-mediated signaling and the expression of STAT3 target genes, thereby inhibiting the proliferation of STAT3-overexpressing tumor cells. STAT3 regulates the transcription of genes involved in several cellular functions. STAT3 is constitutively activated in a variety of human cancers and plays a key role in neoplastic transformation, uncontrolled tumor cell proliferation, resistance to apoptosis, metastasis, immune evasion, tumor angiogenesis, epithelial-mesenchymal transition (EMT) and the Warburg effect.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:VVD 130850
VVD-130850
VVD130850
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search